Journal of Cancer Research and Clinical Oncology

, Volume 129, Issue 8, pp 472–476 | Cite as

Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma

  • Vincenzo Serretta
  • Carlo Pavone
  • Rosalinda Allegro
  • Marco Vella
  • Rosario Sanguedolce
  • Rossana Porcasi
  • Vincenza Morello
  • Rosa Maria Tomasino
  • Michele Pavone-Macaluso
Original Paper

Abstract

Purpose

To study GP-170 in superficial bladder cancer at initial diagnosis and at recurrence and to evaluate if intravesical chemoprophylaxis modifies the expression of GP-170 in tumor recurrences.

Materials and methods

GP-170 was retrospectively assessed in 160 patients affected by primary superficial transitional cell carcinoma of the bladder and followed for up to 10 years. Eighty-four patients (52.5%) recurred after transurethral resection (TUR). Adjuvant intravesical chemotherapy after TUR was adopted in 52 patients. The correlations between GP-170 and G-grade, T-category, risk of recurrence and of progression, and adoption of adjuvant intravesical chemotherapy were investigated. The correlations between variations in grade and stage at recurrence and modifications in GP-170 expression were also studied.

Results

No significant correlation between GP-170 expression and G-grade and T-category was found. A significant correlation was detected between GP-170 expression and recurrence (P=0.0383). It showed a biphasic pattern, i.e., tumors that did not express GP-170 had a higher recurrence rate, but high GP-170 levels were also associated with an increasing risk of recurrence. Intravesical chemotherapy did not induce significative variations in GP-170 expression. No correlation was found between progression and GP-170.

Conclusion

GP-170 seems to be an independent prognostic factor for recurrence in superficial bladder tumors. A negative GP-170 pattern and high levels of GP-170 are associated with an increasing risk of recurrence but have no impact upon progression. In our experience, GP-170 is neither induced nor modified by intravesical chemotherapy, although it might represent a factor of chemoresistance when strongly expressed.

Keywords

Superficial bladder carcinoma GP-170 MDR-1 Prognosis Intravesical chemotherapy 

Notes

Acknowledgements

The study was supported by a grant from the Associazione Italiana per la Ricerca sul Cancro (AIRC) and from a grant (No R1D470PQ52001) from the Ministero Italiano dell' Istruzione, Università e Ricerca (MIUR). Statistical analysis was conducted by Rosalinda Allegro.

References

  1. Kim WJ, Kakehi Y, Yoshida O (1997) Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells. Int J Urol 4:583–590PubMedGoogle Scholar
  2. Kubo H, Sumizawa T, Koga K, Nishiyama K, Takebayashi Y, Chuman Y, Furukawa T, Akiyama S, Ohi Y (1996) Expression of the multidrug resistance-associated protein (MRP) gene in urothelial carcinomas. Int J Cancer 69:488–494PubMedGoogle Scholar
  3. Nakagawa M, Emoto A, Nasu N, Hanada T, Kuwano M, Cole SP, Nomura Y (1997) Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer. J Urol 157:1260–1264PubMedGoogle Scholar
  4. Nargund VH, Lowe J, Flannigan GM, Hamilton Stewart PA (1997) Role of P-glycoprotein in chemoresistant superficial bladder tumours. Eur Urol 31:160–162PubMedGoogle Scholar
  5. Nezasa S, Fujihiro S, Deguchi T, Kawada Y, Kawamoto S, Tamaki M, Yamada S, Okano M (1997) Analysis of induction of MDR1 gene expression by anticancer chemotherapy in bladder cancer. Hinyokika Kiyo 43:629–636PubMedGoogle Scholar
  6. Nooter K, Westerman AM, Flens MJ, Zaman GJ, Scheper RJ, van Wingerden KE, Burger H, Oostrum R, Boersma T, Sonneveld P, et al (1995) Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 11:1301–1310Google Scholar
  7. Schuldes H, Dolderer JH, Schoch C, Bickeböller R, Woodcock BG (2000) Cytostatic sensitivity and MDR in bladder carcinoma cells: implications for tumor therapy. Int J Clin Pharmacol Ther 38:204–208PubMedGoogle Scholar
  8. Tada Y, Wada M, Kuroiwa K, Kinugawa N, Harada T, Nagayama J, Nakagawa M, Naito S, Kuwano M (2000) MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res 6:4618–4627PubMedGoogle Scholar
  9. Toth K, Vaughan MM, Slocum HK, Arredondo MA, Takida H, Baker RM, Rustum YM (1993) New immunohistochemical "sandwich" staining method for mdr-1 p-glycoprotein detection with JSB-1 monoclonal antibody in formalin fixed, paraffin-embedded human tissues. Proc Am Assoc Cancer Res 34:312Google Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Vincenzo Serretta
    • 1
  • Carlo Pavone
    • 1
  • Rosalinda Allegro
    • 1
  • Marco Vella
    • 1
  • Rosario Sanguedolce
    • 2
  • Rossana Porcasi
    • 3
  • Vincenza Morello
    • 3
  • Rosa Maria Tomasino
    • 3
  • Michele Pavone-Macaluso
    • 1
  1. 1.Section of Urology, Department of Internal Medicine, Cardiovascular and Nephro-Urological DiseasesUniversity of PalermoPalermo
  2. 2.Institute of Pathological AnatomyUniversity of PalermoItaly
  3. 3.Institute of PharmacologyUniversity of PalermoItaly

Personalised recommendations